The PARTNER trial and CoreValve High-Risk trial characterized surgical aortic valve replacement (SAVR) valves as having inferior emodynamics to transcatheter aortic valve replacement (TAVR), as shown.
Significantly higher gradients with savr1,2
Average Mean Gradient at One Year*
Significantly more ppm with savr3,4
Severe Prosthesis-Patient Mismatch(PPM) Incidence at One Year*
Given these findings, it is particularly important to consider the hemodynamic performance of various SAVR valves—in particular the Trifecta valve with Glide Technology (GT).